Moderna Stock Plummets Despite Positive Melanoma Vaccine Trial Results
Moderna's shares dropped over 17% despite promising Phase 3 results for its personalized melanoma vaccine developed with Merck.
Moderna's shares dropped over 17% despite promising Phase 3 results for its personalized melanoma vaccine developed with Merck. This is an original TLT brief synthesising 2 outlets (The Crypto Basic, Blockonomi), plus live market data, as of Sat, 24 Oct 2026 00:45:02 UTC.
The development highlights the disconnect between positive clinical outcomes and investor sentiment, raising questions about market expectations for biotech innovations. The 42% reduction in cancer recurrence risk demonstrates significant potential for improving cancer treatment outcomes.
- Moderna's melanoma vaccine reduced cancer recurrence risk by 42% when combined with Keytruda.
- Shares fell 17% to $202.63 despite meeting key clinical goals.
- Market reaction suggests investor concerns beyond positive trial results.
Both The Crypto Basic and Blockonomi report that Moderna's stock dropped over 17% to $202.63 on Thursday, despite the successful Phase 3 trial results of its personalized melanoma vaccine developed with Merck. The vaccine, when combined with Merck's Keytruda, showed a 42% reduction in cancer recurrence risk and a 38% reduction in the risk of distant metastasis or death compared to Keytruda alone. The Crypto Basic emphasizes the market's negative reaction, while Blockonomi focuses on the broader context of biotech stock movements.
Moderna's stock experienced a significant decline on Thursday, dropping more than 17% to $202.63 during regular trading hours. This downturn occurred despite the release of positive Phase 3 trial results for its personalized melanoma vaccine, intismeran autogene, developed in collaboration with Merck.
The vaccine, when combined with Merck's immunotherapy Keytruda, demonstrated a 42% reduction in the risk of cancer recurrence or death and a 38% reduction in the risk of distant metastasis or death compared to Keytruda alone. These results indicate a substantial improvement in treatment efficacy.
The market's negative reaction, as reported by The Crypto Basic and Blockonomi, suggests that investors may have been expecting even more significant results or were concerned about other factors. This reaction is noteworthy given the strong clinical outcomes and the potential impact on cancer treatment.
In the broader market context, the total crypto market cap stands at $2.78 trillion, with 
Bitcoin showing a slight 24-hour decline of 0.22%. The Fear & Greed Index remains at 51, indicating a neutral market sentiment. This context suggests that the market's reaction to Moderna's news is not influenced by broader crypto market trends.
The discrepancy between positive clinical results and stock performance underscores the complex factors influencing investor decisions in the biotech sector. It remains to be seen how the market will respond in the coming days and whether further developments or regulatory updates could shift sentiment.
Figures and sectors in this story, checked live against on-chain aggregators · October 24, 2026.
TLT reads these figures directly from on-chain aggregators (DeFiLlama, mempool.space) at build time — independent of what any outlet reported. Sector totals aggregate every protocol DeFiLlama tracks in that category. Values are live and will change.
Moderna Stock Plummets Despite Positive Melanoma Vaccine Tri — questions & answers
What were the results of Moderna's melanoma vaccine trial?
The vaccine reduced cancer recurrence risk by 42% and distant metastasis risk by 38% when combined with Keytruda.
Why did Moderna's stock drop despite positive trial results?
The market may have been expecting even better results or reacted to other factors not directly related to the trial.
How does this affect the broader market?
The broader crypto market remains relatively stable, with no significant impact from Moderna's news.
Which outlets reported this story?
This is an original TLT brief that synthesises reporting from The Crypto Basic, Blockonomi, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.